19:28 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived oligocortical spheroids could be used to study demyelinating diseases and screen therapies to treat them. The spheroids were generated by culturing human pluripotent stem cells with platelet derived growth factor AA...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
14:16 , Apr 18, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models A method for differentiating hPSCs into specific cell types by expressing select transcription factors could aid the development of cell-based disease models. The method involved engineering hPSCs via CRISPR-associated protein 9 (Cas9)-guided...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Emixustat: Phase II started

Acucela began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate once-daily oral emixustat for 12 weeks in 20 patients. Doses of emixustat will be doubled each week until week 4, after which patients will...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Tendoncel: Phase II data

A double-blind, placebo-controlled Phase II trial in 34 patients with chronic grade 3 lateral epicondylitis showed that once-daily topical Tendoncel for 21 days significantly improved DASH scores by 70% and PRTEE scores by 74%. Tendoncel...